Endocrinology · Medical Literature
Feasibility and preliminary biomarker responses to capsules containing green coffee extract enriched with magnesium di-malate in women with type 2 diabetes mellitus: a randomized, placebo-controlled pilot trial.
Abstract
To evaluate the feasibility of a 12-week, randomized, double-blind, placebo-controlled intervention with capsules containing green coffee extract enriched with magnesium di-malate in women with type 2 diabetes mellitus, including overall adherence to capsule use and tolerability, as well as to explore preliminary between-group differences in glycemic and cardiovascular biomarkers. This randomized, double-blind, placebo-controlled pilot trial included 48 eligible women with type 2 diabetes mellitus, equally assigned to the placebo group (n=24) or the experimental group (n=24). Participants received capsules daily for 12 weeks and were followed up through nursing consultations. Overall retention was 83.3% (40/48), and overall adherence to capsule use was estimated at over 82%. Glycemic biomarkers included fasting glucose, estimated mean glucose, HbA1c, insulin, HOMA-IR, and HOMA-β. Cardiovascular biomarkers included urea, creatinine, uric acid, apolipoprotein B, triglycerides, and the triglycerides-glucose index. Data were analyzed based on avail-able data from participants who completed follow-up and the final evaluation. The protocol was feasible under the study conditions, although retention differed between groups. Glycemic biomarkers varied during follow-up in both groups, without conclusive evidence of a consistent between-group effect. In the experimental group, triglycerides and the triglycerides-glucose index showed numerical reductions, while uric acid fluctuated in both groups. These findings should be interpreted as exploratory. This pilot trial provided preliminary information on the feasibility of implementing this intervention in women with type 2 diabetes mellitus. The biomarker findings were exploratory and imprecise and do not allow for definitive conclusions on efficacy.
Clinical relevance
This pilot trial addresses a gap in the evidence base regarding nutraceutical adjuncts for glycemic and cardiovascular risk management in women with type 2 diabetes mellitus (T2DM), a population bearing a disproportionate cardiometabolic burden. Green coffee extract (a source of chlorogenic acids with putative insulin-sensitizing properties) combined with magnesium di-malate (which may support glucose metabolism and mitochondrial function) has not been rigorously evaluated in this demographic. Clinicians managing T2DM in women with suboptimal pharmacological control or interest in adjunctive therapies should be aware of this early-phase feasibility data before extrapolating any efficacy claims.
Key findings
1. Study design: 12-week, randomized, double-blind, placebo-controlled pilot trial in 48 women with T2DM, equally allocated to experimental (n=24) or placebo (n=24) arms, with daily capsule administration and nursing consultation follow-up. 2. Retention: Overall retention was 83.3% (40/48 participants completed follow-up), though the abstract notes that retention differed between the two groups — a methodologically important feasibility signal that could introduce attrition bias in a future definitive trial. 3. Adherence: Overall adherence to capsule use was estimated at >82%, suggesting the intervention is acceptable and practically deliverable in this population under the study conditions. 4. Glycemic biomarkers (fasting glucose, estimated mean glucose, HbA1c, insulin, HOMA-IR, HOMA-β): Values varied during follow-up in both groups, but no conclusive evidence of a consistent between-group treatment effect was identified; specific effect sizes, confidence intervals, and p-values were not reported in the abstract. 5. Cardiovascular biomarkers — lipid/metabolic indices: Numerical reductions in triglycerides and the triglycerides-glucose index (TyG index) were observed in the experimental group; however, no inferential statistics (magnitude of difference, 95% CI, or p-values) are provided, precluding efficacy conclusions. 6. Uric acid: Fluctuated in both groups without a discernible directional pattern attributable to the intervention; no quantitative between-group data reported.
Practice implications
Clinicians should not incorporate green coffee extract enriched with magnesium di-malate into routine T2DM management based on this trial alone, as the findings are explicitly exploratory, imprecise, and insufficient to establish efficacy for glycemic or cardiovascular endpoints. The >82% adherence and 83.3% retention rates support the feasibility of conducting a larger, adequately powered RCT in women with T2DM, which should prospectively stratify by baseline HbA1c, background antidiabetic therapy, and menopausal status to reduce confounding. The numerical signals in triglycerides and the TyG index — a surrogate of insulin resistance and cardiovascular risk — warrant quantification with appropriate power calculations in future trials, particularly given the known cardiometabolic risk trajectory in women with T2DM.